Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

@article{Huang2010RespiratorySV,
  title={Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.},
  author={Kelly Huang and Len Incognito and Xing Cheng and Nancy D Ulbrandt and Herren Wu},
  journal={Journal of virology},
  year={2010},
  volume={84 16},
  pages={
          8132-40
        }
}
Respiratory syncytial virus (RSV) is a major cause of virus-induced respiratory disease and hospitalization in infants. Palivizumab, an RSV-neutralizing monoclonal antibody, is used clinically to prevent serious RSV-related respiratory disease in high-risk infants. Motavizumab, an affinity-optimized version of palivizumab, was developed to improve protection against RSV. These antibodies bind RSV F protein, which plays a role in virus attachment and mediates fusion. Determining how these… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function

  • The Journal of general virology
  • 2013
VIEW 7 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Development of Antibody Therapeutics against Flaviviruses

  • International journal of molecular sciences
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 59 REFERENCES

Antibodies against viruses: passive and active immunization.

  • Current opinion in immunology
  • 2008
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Respiratory syncytial virus and metapneumovirus, p. 1601–1645

P. L. Collins, J. E. Crowe, Jr.
  • Fields virology, 5th ed.,
  • 2007
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…